Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...
A groundbreaking study led by Li Yi, professor at the School of Life Sciences, was published in Nature on March 12, titled “Perception of viral infections and initiation of antiviral defence in rice”, ...
Fintel on MSN5d
Leerink Partners Initiates Coverage of Nurix Therapeutics (NRIX) with Market Perform RecommendationFintel reports that on March 17, 2025, Leerink Partners initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a ...
A groundbreaking study led by Li Yi, professor at the School of Life Sciences, was published in Nature on March 12, titled "Perception of viral ...
The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...
This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback